Nasdaq · Healthcare
FENNEC PHARMACEUTICALS INC. (FENC)
As-reported financials and recent SEC filings for FENNEC PHARMACEUTICALS INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$44.6M
Net income
$-9.7M
Net margin
-21.8%
Diluted EPS
$-0.34
ROE
-27.5%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $44.6M | $47.5M | $21.3M | $1.5M | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-6.3M | $2.6M | $-12.8M | $-22.6M | $-17.2M |
| Net income | $-9.7M | $-436,000 | $-16.0M | $-23.7M | $-17.3M |
| Diluted EPS | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.67 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →42026-07-01
View on EDGAR →42026-07-01
View on EDGAR →42026-07-01
View on EDGAR →1442026-07-01
View on EDGAR →42026-07-01
View on EDGAR →42026-07-01
View on EDGAR →S-82026-06-11
View on EDGAR →Largest Healthcare peers
Go deeper on FENC
Search FENNEC PHARMACEUTICALS INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.